{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:21Z","timestamp":1794047421634,"version":"4.8.0"},"reference-count":32,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy studied in patients with multiple myeloma exposed to three classes of treatment in the single-arm CARTITUDE-1 study. To assess the effectiveness of cilta-cel compared to real-world clinical practice (RWCP), we performed adjusted comparisons using individual patients\u2019 data from CARTITUDE-1 and LocoMMotion, a prospective, multinational study of patients with multiple myeloma triple-class exposed of treatment. Comparisons were performed using inverse probability weighting. In CARTITUDE-1, 113 patients were enrolled, and 97 patients were infused with cilta-cel. In LocoMMotion, 248 patients were enrolled, and 170 patients were included in the comparisons versus infused patients. Ninety-two unique regimens were used in LocoMMotion, most frequently carfilzomib-dexamethasone (13.7%), pomalidomide-cyclophosphamide-dexamethasone (13.3%) and pomalidomidedexamethasone (11.3%). Adjusted comparisons showed that patients treated with cilta-cel were 3.12-fold more likely to respond to treatment than those managed by RWCP (response rate, 3.12, 95% confidence interval [95% CI]: 2.24-4.00), had their risk of progression or death reduced to by 85% (progression-free survival hazard ratio=0.15, 95% CI: 0.08-0.29), and a risk of death lowered by 80% (overall survival hazard ratio HR=0.20, 95% CI: 0.09-0.41). The incremental improvement in healthrelated quality of life from baseline for cilta-cel versus RWCP at week 52, as measured by EORTC QLQ-C30 Global Health Status, was 13.4 (95% CI: 3.5-23.6) and increased to 30.8 (95% CI: 21.8-39.8) when including death as additional information regarding patients\u2019 health status. Patients treated with cilta-cel experienced more adverse events than those managed with RWCP (any grade: 100% vs. 83.5%). The results from this study demonstrate improved efficacy outcomes of cilta-cel versus RWCP and highlight its potential as a novel and effective treatment option for patients with multiple myeloma triple-class exposed of antimyeloma treatment. CARTITUDE-1 is registered with clinicaltrials gov. Identifier: NCT03548207. LocoMMotion is registered with clinicaltrials gov. Identifier: NCT04035226.<\/jats:p>","DOI":"10.3324\/haematol.2022.280482","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:18:45Z","timestamp":1671718725000},"page":"2192-2204","source":"Crossref","is-referenced-by-count":18,"title":["Adjusted comparison of outcomes between patients from CARTITUDE-1 &lt;i&gt;versus&lt;\/i&gt; multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice"],"prefix":"10.3324","volume":"108","author":[{"given":"Maria-Victoria","family":"Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ghilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpike","family":"Thilakarathne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolen J.","family":"Perualila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedelyn","family":"Cabrieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haefliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Erler-Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Hague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Strulev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Nesheiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"50671","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23(1):3-9.","DOI":"10.1038\/leu.2008.291"},{"key":"50672","doi-asserted-by":"crossref","unstructured":"Raab MS, Cavo M, Delforge M. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016; 175(1):66-76.","DOI":"10.1111\/bjh.14193"},{"key":"50673","doi-asserted-by":"crossref","unstructured":"Benyamini N, Adir S, Gatt ME. Real-life data on the outcome of daratumomab-refractory myeloma patients: multicenter experience. Blood. 2018; 132(Suppl_1):3259.","DOI":"10.1182\/blood-2018-99-115985"},{"key":"50674","unstructured":"Haefliger B, Diels J, Ghilotti F. Baseline characteristics and survival outcomes of patients with tri-exposed multiple myeloma in a German registry. Proceedings of the EHA2021-European Hematology Association Conference."},{"key":"50675","doi-asserted-by":"crossref","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-1403.","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"50676","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Nahi H, Plesner T. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020; 7(6):e447-e455.","DOI":"10.1016\/S2352-3026(20)30081-8"},{"key":"50677","doi-asserted-by":"crossref","unstructured":"Miguel JS, Weisel K, Moreau P. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11):1055-1066.","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"50678","doi-asserted-by":"crossref","unstructured":"San-Miguel JF, Hungria VT, Yoon SS. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014; 15(11):1195-1206.","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"50679","doi-asserted-by":"crossref","unstructured":"Orlowski RZ, Nagler A, Sonneveld P. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25(25):3892-3901.","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"50680","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Palumbo A. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17(1):27-38.","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"50681","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Chen C, Spencer A. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23(11):2147-2152.","DOI":"10.1038\/leu.2009.147"},{"key":"50682","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):309-322.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"50683","doi-asserted-by":"crossref","unstructured":"Gandhi UH, Cornell RF, Lakshman A. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"50684","doi-asserted-by":"crossref","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018; 70:199-208.","DOI":"10.1016\/j.ctrv.2018.09.001"},{"key":"50685","doi-asserted-by":"crossref","unstructured":"Kumar V, Ailawadhi M, Dutta N. Trends in early mortality from multiple myeloma: a population-based analysis. Clin Lymphoma Myeloma Leuk. 2021; 21(5):e449-e455.","DOI":"10.1016\/j.clml.2020.12.023"},{"key":"50686","doi-asserted-by":"crossref","unstructured":"Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019; 25(9):1341-1355.","DOI":"10.1038\/s41591-019-0564-6"},{"key":"50687","doi-asserted-by":"crossref","unstructured":"Madduri D, Berdeja JG, Usmani SZ. CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma. Blood. 2020; 136(Suppl 1):22-25.","DOI":"10.1182\/blood-2020-136307"},{"key":"50688","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"50689","unstructured":"A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). 2020."},{"key":"50690","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Weisel K, Stefano VD. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed\/refractory multiple myeloma (RRMM) receiving \u22653 prior lines of therapy. J Clin Oncol. 2021; 39(Suppl 15):S8041.","DOI":"10.1200\/JCO.2021.39.15_suppl.8041"},{"key":"50691","doi-asserted-by":"crossref","unstructured":"Mateos MV, Weisel K, De Stefano V. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022; 36(5):1371-1376.","DOI":"10.1038\/s41375-022-01531-2"},{"key":"50692","doi-asserted-by":"crossref","unstructured":"Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019; 188(1):250-257.","DOI":"10.1093\/aje\/kwy201"},{"key":"50693","doi-asserted-by":"crossref","unstructured":"Martin T, Lin Y, Agha M. Health-related quality of life in the CARTITUDE-1 study of ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2020; 136(Suppl_1):41-42.","DOI":"10.1182\/blood-2020-136368"},{"key":"50694","doi-asserted-by":"crossref","unstructured":"Ratcliffe J, Young T, Longworth L, Buxton M. An assessment of the impact of informative dropout and nonresponse in measuring health-related quality of life using the EuroQol (EQ-5D) descriptive system. Value Health. 2005; 8(1):53-58.","DOI":"10.1111\/j.1524-4733.2005.03068.x"},{"key":"50695","doi-asserted-by":"crossref","unstructured":"Patel D, Grimson F, Mihaylova E. Use of external comparators for Health Technology Assessment submissions based on single-arm trials. Value Health. 2021; 24(8):1118-1125.","DOI":"10.1016\/j.jval.2021.01.015"},{"key":"50696","doi-asserted-by":"crossref","unstructured":"Goring S, Taylor A, M\u00fcller K. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019; 9(2):e024895.","DOI":"10.1136\/bmjopen-2018-024895"},{"key":"50697","doi-asserted-by":"crossref","unstructured":"Costa LJ, Lin Y, Martin TG. Cilta-cel versus conventional treatment in patients with relapse\/refractory multiple myeloma. J Clin Oncol. 2021; 39(15_suppl):8030.","DOI":"10.1200\/JCO.2021.39.15_suppl.8030"},{"key":"50698","unstructured":"Weisel K, Martin T, Krishnan A. Comparison of ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus standard of care in triple-class exposed multiple myeloma patients in clinical trials of daratumumab. Proceedings of the EHA2021-European Hematology Association Conference. Abstract EP977."},{"key":"50699","doi-asserted-by":"crossref","unstructured":"Martin TG, Krishnan AY, Yong K. Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2021; 39(Suppl 15):S8045.","DOI":"10.1200\/JCO.2021.39.15_suppl.8045"},{"key":"50700","doi-asserted-by":"crossref","unstructured":"Perrot A, Lauwers-Cances V, Tournay E. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019; 37(19):1657-1665.","DOI":"10.1200\/JCO.18.00776"},{"key":"50701","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(6):801-812.","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"50702","doi-asserted-by":"crossref","unstructured":"Merz M, Goldschmidt H, Hari P. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD-38 from a German Registry. Cancers (Basel). 2021; 13(23):5996.","DOI":"10.3390\/cancers13235996"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280482\/75121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280482\/75892","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10910\/75121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:06Z","timestamp":1794045786000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.280482","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}